Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04LAQ
|
|||
Former ID |
DIB009061
|
|||
Drug Name |
Candoxatrilat
|
|||
Synonyms |
Candoxatrilat < Rec INN; UK-69578; UK-73967; Cis-4-[[[1-[2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; (+)-cis-4-[1-[(S)-2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentylcarbonylamino]cyclohexanecarboxylic acid; 3-[1-(4-cis-Carboxycyclohexylcarbamoyl)cyclopentyl]-2(R,S)-(2-methoxyethoxymethyl)propanoic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Heart failure [ICD-11: BD10-BD13; ICD-10: I50, I50.9; ICD-9: 428] | Discontinued in Phase 1 | [1], [2] | |
Structure |
![]() |
Download2D MOL |
||
Formula |
C20H33NO7
|
|||
Canonical SMILES |
COCCOCC(CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)O
|
|||
InChI |
1S/C20H33NO7/c1-27-10-11-28-13-15(18(24)25)12-20(8-2-3-9-20)19(26)21-16-6-4-14(5-7-16)17(22)23/h14-16H,2-13H2,1H3,(H,21,26)(H,22,23)(H,24,25)/t14?,15-,16?/m0/s1
|
|||
InChIKey |
ACZWIDANLCXHBM-PCKAHOCUSA-N
|
|||
CAS Number |
CAS 123122-54-3
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:3354
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Neutral endopeptidase (MME) | Target Info | Inhibitor | [3], [4] |
KEGG Pathway | Renin-angiotensin system | |||
Hematopoietic cell lineage | ||||
Protein digestion and absorption | ||||
Alzheimer's disease | ||||
NetPath Pathway | EGFR1 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
Primary Focal Segmental Glomerulosclerosis FSGS | ||||
Alzheimers Disease |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6491). | |||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001740) | |||
REF 3 | Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7. | |||
REF 4 | The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.